Cargando…

Computational screening of camostat and related compounds against human TMPRSS2: A potential treatment of COVID-19

The global coronavirus pandemic has burdened the human population with mass fatalities and disastrous socio-economic consequences. The frequent occurrence of these new variants has fueled the already prevailing challenge. There is still a necessity for highly effective small molecular agents to prev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sharma, Tanuj, Baig, Mohammad Hassan, Khan, Mohd Imran, Alotaibi, Saqer S., Alorabi, Mohammed, Dong, Jae-June
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787670/ https://www.ncbi.nlm.nih.gov/pubmed/35095307 http://dx.doi.org/10.1016/j.jsps.2022.01.005

Ejemplares similares

Impact of the Double Mutants on Spike Protein of SARS-CoV-2 B.1.617 Lineage on the Human ACE2 Receptor Binding: A Structural Insight
por: Khan, Mohd Imran, et al.
Publicado: (2021)

Screening of inhibitors against SARS-CoV-2 spike protein and their capability to block the viral entry mechanism: A viroinformatics study
por: Farouk, Abd-ElAziem, et al.
Publicado: (2021)

Structural Basis of Covalent Inhibitory Mechanism of TMPRSS2-Related Serine Proteases by Camostat
por: Sun, Gaohui, et al.
Publicado: (2021)

Screening of drug databank against WT and mutant main protease of SARS-CoV-2: Towards finding potential compound for repurposing against COVID-19
por: Sharma, Tanuj, et al.
Publicado: (2021)

Spontaneous binding of potential COVID-19 drugs (Camostat and Nafamostat) to human serine protease TMPRSS2
por: Zhu, Haixia, et al.
Publicado: (2020)

Molecular mechanism of inhibiting the SARS-CoV-2 cell entry facilitator TMPRSS2 with camostat and nafamostat
por: Hempel, Tim, et al.
Publicado: (2020)

Low risk of the TMPRSS2 inhibitor camostat mesylate and its metabolite GBPA to act as perpetrators of drug-drug interactions
por: Weiss, Johanna, et al.
Publicado: (2021)

Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial.
por: Gunst, Jesper D., et al.
Publicado: (2021)

Structural modeling and analysis of the SARS-CoV-2 cell entry inhibitor camostat bound to the trypsin-like protease TMPRSS2
por: Escalante, Diego E., et al.
Publicado: (2021)

Camostat mesilate therapy for COVID-19
por: Uno, Yoshiharu
Publicado: (2020)

Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity
por: Hoffmann, Markus, et al.
Publicado: (2020)

Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity
por: Hoffmann, Markus, et al.
Publicado: (2021)

A phase I study of high dose camostat mesylate in healthy adults provides a rationale to repurpose the TMPRSS2 inhibitor for the treatment of COVID‐19
por: Kitagawa, Junsaku, et al.
Publicado: (2021)

Structural insights and inhibition mechanism of TMPRSS2 by experimentally known inhibitors Camostat mesylate, Nafamostat and Bromhexine hydrochloride to control SARS-coronavirus-2: A molecular modeling approach
por: Sonawane, Kailas D., et al.
Publicado: (2021)

Camostat Does Not Inhibit the Proteolytic Activity of Neutrophil Serine Proteases
por: Assylbekova, Akmaral, et al.
Publicado: (2022)

Strong Binding of Leupeptin with TMPRSS2 Protease May Be an Alternative to Camostat and Nafamostat for SARS-CoV-2 Repurposed Drug: Evaluation from Molecular Docking and Molecular Dynamics Simulations
por: Ramakrishnan, Jaganathan, et al.
Publicado: (2021)

Is PF-00835231 a Pan-SARS-CoV-2 Mpro Inhibitor? A Comparative Study
por: Baig, Mohammad Hassan, et al.
Publicado: (2021)

Acute eosinophilic pneumonia caused by camostat mesilate: The first case report
por: Ota, Shinichiro, et al.
Publicado: (2016)

Camostat mesylate therapy in critically ill patients with COVID-19 pneumonia
por: Sakr, Yasser, et al.
Publicado: (2021)

Development of machine learning models for the screening of potential HSP90 inhibitors
por: Khan, Mohd Imran, et al.
Publicado: (2022)

Simultaneous Treatment of COVID-19 With Serine Protease Inhibitor Camostat and/or Cathepsin L Inhibitor?
por: Bittmann, Stefan, et al.
Publicado: (2020)

Investigating the Mechanism of Inhibition of Cyclin-Dependent Kinase 6 Inhibitory Potential by Selonsertib: Newer Insights Into Drug Repurposing
por: Baig, Mohammad Hassan, et al.
Publicado: (2022)

Semi-Mechanistic Pharmacokinetic-Pharmacodynamic Model of Camostat Mesylate-Predicted Efficacy against SARS-CoV-2 in COVID-19
por: Kosinsky, Yuri, et al.
Publicado: (2022)

Removal of Biomass and Nutrients by Weeds and Direct-Seeded Rice under Conservation Agriculture in Light-Textured Soils of North-Western India
por: Dhaliwal, Salwinder Singh, et al.
Publicado: (2021)

Camostat Mesylate May Reduce Severity of Coronavirus Disease 2019 Sepsis: A First Observation
por: Hofmann-Winkler, Heike, et al.
Publicado: (2020)

Discovery of TMPRSS2 inhibitors from virtual screening
por: Hu, Xin, et al.
Publicado: (2021)

Inhibition of Listeria Monocytogenes HtrA Protease with Camostat, Gabexate and Nafamostat Mesylates and the Binding Mode of the Inhibitors
por: C, Amrutha M, et al.
Publicado: (2023)

Biocomputational Screening of Natural Compounds against Acetylcholinesterase
por: Ahmad, Syed Sayeed, et al.
Publicado: (2021)

Paecilomyces formosus MD12, a Biocontrol Agent to Treat Meloidogyne incognita on Brinjal in Green House
por: Baazeem, Alaa, et al.
Publicado: (2021)

Identification of potential Indonesian marine invertebrate bioactive compounds as TMPRSS2 and SARS-CoV-2 Omicron spike protein inhibitors through computational screening
por: Rizka Nurcahyaningtyas, Haviani, et al.
Publicado: (2023)

Discovery of novel acetylcholinesterase inhibitors through integration of machine learning with genetic algorithm based in silico screening approaches
por: Khan, Mohd Imran, et al.
Publicado: (2023)

Safety Evaluation and Population Pharmacokinetics of Camostat Mesylate and Its Major Metabolites Using a Phase I Study
por: Kim, Gwanyoung, et al.
Publicado: (2023)

Novel Compound Heterozygous TMPRSS15 Gene Variants Cause Enterokinase Deficiency
por: Wang, Lan, et al.
Publicado: (2020)

Screening of inhibitors for S130G inhibitor resistant mutants of TEM type beta-lactamase
por: Baig, Mohd Hassan, et al.
Publicado: (2012)

Repurposing Anti-Dengue Compounds against Monkeypox Virus Targeting Core Cysteine Protease
por: Imran, Mohd, et al.
Publicado: (2023)

Virtual Screening on Marine Natural Products for Discovering TMPRSS2 Inhibitors
por: Mahmudpour, Mehdi, et al.
Publicado: (2021)

In Silico Screening of Novel TMPRSS2 Inhibitors for Treatment of COVID-19
por: Wang, Shuo, et al.
Publicado: (2022)

Combination Treatment of Omega-3 Fatty Acids and Vitamin C Exhibited Promising Therapeutic Effect against Oxidative Impairment of the Liver in Methotrexate-Intoxicated Mice
por: Alorabi, Mohammed, et al.
Publicado: (2022)

Computational Identification of a Putative Allosteric Binding Pocket in TMPRSS2
por: Sgrignani, Jacopo, et al.
Publicado: (2021)

The serine protease inhibitor camostat inhibits influenza virus replication and cytokine production in primary cultures of human tracheal epithelial cells
por: Yamaya, Mutsuo, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_e45ej0lk9nof491rh2i9n76pr2